Navigation Links
Battelle to Perform Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process
Date:10/28/2008

CAMBRIDGE, Mass. and COLUMBUS, Ohio, Oct. 28 /PRNewswire/ -- IntelligentMDx a developer and manufacturer of proprietary nucleic acid assays, today announced that it is working with the Battelle Eastern Science and Technology (BEST) Center to conduct assay performance verification studies of its nucleic acid-based diagnostic or 'smart' molecular diagnostic assays.

Under terms of the agreement Battelle will perform various testing of IntelligentMDx's Quantitative BK Virus (BKV) Real-Time PCR Assay to identify its performance characteristics. Financial terms of the agreement were not disclosed.

BKV has recently emerged as an important pathogen in nephropathy in kidney transplant patients and hemorrhagic cystitis in human stem cell transplant patients. The IntelligentMDx Quantitative BK Virus Real-Time PCR Assay can be utilized to track the course of infection and monitor response to treatment.

The biggest hurdle for a nucleic acid testing is that current reagent design methods do not specifically address the core set of challenge affecting reagent performance -- such as genetic diversity and other key performance metrics. IntelligentMDx has a proprietary process to manage the design, development and manufacturing of pathogen assays that are platform agnostic and adaptable to all nucleic acid detection methodologies. The IntelligentMDx process allows for rapid time to market.

About IntelligentMDx

IntelligentMDx(TM) develops and manufactures tests, under regulatory compliance, for a broad range of molecular based systems for use in clinical molecular diagnostics, drug development and applied science applications. Our mission is to rapidly translate the needs of the clinician, patient and partners into very specific, highly sensitive, robust clinically impactful tests, thus enabling caregivers worldwide to provide care with certainty(SM).

IntelligentMDx's competitive advantage incorporates intelligent software with assay development and manufacturing expertise within a Quality System compliant with both ISO and FDA current regulations. Our uniquely integrated modular test development process provides clinically impactful and novel nucleic-acid testing solutions including Real-Time PCR assays. The company is working to use its proprietary "symptom-based diagnostics" approach for disease detection. Our goal is to provide the end users with "smart" tests that detect several related diseases at once -- more quickly and more economically than current standard individual tests. The quality and breadth of our product candidate pipeline, platform-agnostic approach, scientific team and strategic collaborations and partnerships is enabling us to become a fully integrated molecular diagnostics company.

About Battelle

Battelle's Global Health and Life Sciences business delivers a comprehensive set of R&D services to solve complex challenges for government health agencies and medical device, biotechnology, and pharmaceutical firms. Including the national laboratories it manages or co-manages, Battelle oversees over $200 million annually in health and life sciences-research contributing to advances in medical devices, pharmaceuticals, public health, and next-generation diagnostics and therapeutics.

Battelle is the world's largest non-profit independent research and development organization, providing innovative solutions to the world's most pressing needs through its four global businesses: Laboratory Management, National Security, Energy Technology, and Health and Life Sciences. It advances scientific discovery and application by conducting $4 billion in global R&D annually through contract research, laboratory management and technology commercialization. Headquartered in Columbus, Ohio, Battelle oversees 20,400 employees in more than 120 locations worldwide, including six national laboratories which Battelle manages or co-manages for the U.S. Department of Energy.

Statements in this release, including those that may relate to revenue growth, trends in financial or operational performance, litigation, new product plans and business prospects are forward-looking statements. Actual results might differ materially from these statements due to risks and uncertainties, including the impact of competitive products and pricing, market acceptance of new products, market conditions and enforcement of intellectual property rights. A more detailed description of these risks and other risks applicable to IntelligentMDx are available upon request from IntelligentMDx. IntelligentMDx disclaims any intent or obligation to update these forward-looking statements.

CONTACT: For more information on IntelligentMDx, visit http://www.IntelligentMD.com or contact Corporate Communications, cc@IntelligentMD.com, 617-871-6400.

For more information on Battelle, visit http://www.battelle.org or contact Public Relations Manager Katy Delaney at (410) 306-8638 or at delaneyk@battelle.org.


'/>"/>
SOURCE IntelligentMDx
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Battelle and YuYu Pharma Create the First Joint Bioequivalence Test Experimentation Institution
2. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
5. End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver
6. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
7. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
8. Physician Team at Northwestern Memorial Performs Rare Oral Gallbladder Removal
9. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
10. The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers
11. New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit ... as the latest addition to its growing list of Partner Firms. S.S. ... Southeast, from Orlando to Huntsville and in between. , Harnessing the experience and ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: ... winner and inspirational speaker Jan Fox will serve as keynote speaker at the ... provide participants with tools to more effectively communicate with their own organizational staff ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... it has been awarded the prestigious Distinguished Emerald Club of the World award, ... by BoardRoom magazine, one of the most respected trade publications serving private clubs. ...
(Date:2/10/2016)... Petaluma, CA (PRWEB) , ... February 10, 2016 , ... ... newest and most versatile series of monitor mounts ever. , “Our goal was ... flexible and easy to install system that we have ever created.” said Darren Hulsey, ...
(Date:2/10/2016)... ... February 09, 2016 , ... A new leadership team for Mid-South ... President Joe Wiley made the announcement Monday night, Feb. 8, prior to the evening ... of FHU and the creator of GO! Camp, has been named director. Gayle McDonald, ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 2016  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced further details of three ... functional aspects of Lewy body dementia, a disease ... Two out of the three studies were recently ... later this quarter. In addition, the Company reported ...
(Date:2/9/2016)... Mass. , Feb. 9, 2016   AllCare ... The Joint Commission,s Gold Seal of Approval ® ... compliance with its performance standards. The Gold Seal of ... reflects an organization,s commitment to providing safe and effective ... AllCare Plus Pharmacy underwent a rigorous on-site survey ...
(Date:2/9/2016)... 9, 2016 The new report "Global Diagnostic Ultrasound Devices ... Consulting group reveals that global diagnostic ultrasound devices market was valued ... US$ 7,466.3 million by 2019 at a CAGR of 6.8% from ... ultrasound market has been analyzed for six geographies of ... Asia-Pacific , Latin America , ...
Breaking Medicine Technology: